Evolving views of telomerase and cancer

Trends in Cell Biology

Volumn 13, Issue 6, 2003, Pages 289-294

  Blasco, Maria A ^a   Hahn, William C ^b  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; TELOMERASE;

AGING; BIOLOGY; CANCER; CARCINOGENESIS; CELL DIVISION; CELL IMMORTALIZATION; CELL SURVIVAL; ENZYME ACTIVATION; GENE EXPRESSION; GENOMICS; HUMAN; NONHUMAN; NUCLEOTIDE REPEAT; OBSERVATION; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TELOMERE;

EUKARYOTA;

EID: 0038359431     PISSN: 09628924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0962-8924(03)00085-0     Document Type: Review

References (59)

1. Blackburn E.H. Telomere states and cell fates. Nature. 408:2000;53-56.
2. DePinho R.A. The age of cancer. Nature. 408:2000;248-254.
3. de Lange T. Protection of mammalian telomeres. Oncogene. 21:2002;532-540.
4. Blasco M.A. Telomeres and cancer: a tale with many endings. Curr. Opin. Genet. Dev. 13:2003;70-76.
5. Blackburn E.H. Switching and signaling at the telomere. Cell. 106:2001;661-673.
6. Counter C.M., et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 11:1992;1921-1929.
7. Artandi S.E., et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature. 406:2000;461-465.
8. Smogorzewska A., de Lange T. Different telomere damage signaling pathways in human and mouse cells. EMBO J. 21:2002;4338-4348.
9. Shay J.W., et al. The frequency of immortalization of human fibroblasts and mammary epithelial cells transfected with SV40 large T-antigen. Exp. Cell Res. 209:1993;45-52.
10. Harley C.B., et al. Telomerase, cell immortality, and cancer. Cold Spring Harb. Symp. Quant. Biol. 59:1994;307-315.
11. Neumann A.A., Reddel R.R. Telomere maintenance and cancer - look, no telomerase. Nat. Rev. Cancer. 2:2002;879-884.
12. Lundblad V., Blackburn E.H. An alternative pathway for yeast telomere maintenance rescues est1- senescence. Cell. 73:1993;347-360.
13. Dunham M.A., et al. Telomere maintenance by recombination in human cells. Nat. Genet. 26:2000;447-450.
14. Wright W.E., Shay J.W. Cellular senescence as a tumor-protection mechanism: the essential role of counting. Curr. Opin. Genet. Dev. 11:2001;98-103.
15. Greenberg R.A., et al. Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse. Cell. 97:1999;515-525.
16. Gonzalez-Suarez E., et al. Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. Nat. Genet. 26:2000;114-117.
17. Chin L., et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell. 97:1999;527-538.
18. Bodnar A.G., et al. Extension of life-span by introduction of telomerase into normal human cells. Science. 279:1998;349-352.
19. Vaziri H., Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr. Biol. 8:1998;279-282.
20. Hahn W.C., et al. Inhibition of telomerase limits the growth of human cancer cells. Nat. Med. 5:1999;1164-1170.
21. Zhang X., et al. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev. 13:1999;2388-2399.
22. Herbert B., et al. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc. Natl. Acad. Sci. U. S. A. 96:1999;14276-14281.
23. Damm K., et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J. 20:2001;6958-6968.
24. Hahn W.C., et al. Creation of human tumor cells with defined genetic elements. Nature. 400:1999;464-468.
25. Rich J.N., et al. A genetically tractable model of human glioma formation. Cancer Res. 61:2001;3556-3560.
26. MacKenzie K.L., et al. Multiple stages of malignant transformation of human endothelial cells modelled by co-expression of telomerase reverse transcriptase, SV40 T antigen and oncogenic N-ras. Oncogene. 21:2002;4200-4211.
27. Brookes S., et al. INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence. EMBO J. 21:2002;2936-2945.
28. Kim N.W., et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 266:1994;2011-2015.
29. Bryan T.M., et al. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat. Med. 3:1997;1271-1274.
30. Blasco M.A., et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell. 91:1997;25-34.
31. Kipling D., Cooke H.J. Hypervariable ultra-long telomeres in mice. Nature. 347:1990;400-402.
32. Lazarov M., et al. CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis. Nat. Med. 8:2002;1105-1114.
33. Blasco M.A., et al. Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis. Nat. Genet. 12:1996;200-204.
34. Seger Y.R., et al. Transformation of normal human cells in the absence of telomerase activation. Cancer Cell. 2:2002;401-413.
35. Kiyono T., et al. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature. 396:1998;84-88.
36. Wei S., Sedivy J.M. Expression of catalytically active telomerase does not prevent premature senescence caused by overexpression of oncogenic Ha-Ras in normal human fibroblasts. Cancer Res. 59:1999;1539-1543.
37. Espejel S., Blasco M.A. Identification of telomere-dependent 'senescence-like' arrest in mouse embryonic fibroblasts. Exp. Cell Res. 276:2002;242-248.
38. Stewart S.A., et al. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc. Natl. Acad. Sci. U. S. A. 99:2002;12606-12611.
39. -/- mice with short telomeres. EMBO Rep. 2:2001;800-807.
40. Hemann M.T., et al. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell. 107:2001;67-77.
41. Counter C.M., et al. Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proc. Natl. Acad. Sci. U. S. A. 95:1998;14723-14728.
42. Chang S., et al. Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression. Genes Dev. 17:2003;88-100.
43. Hiyama E., Hiyama K. Clinical utility of telomerase in cancer. Oncogene. 21:2002;643-649.
44. Prowse K.R., Greider C.W. Developmental and tissue-specific regulation of mouse telomerase and telomere length. Proc. Natl. Acad. Sci. U. S. A. 92:1995;4818-4822.
45. Shay J.W., Wright W.E. Quantitation of the frequency of immortalization of normal human diploid fibroblasts by SV40 large T-antigen. Exp. Cell Res. 184:1989;109-118.
46. Hahn W.C., Weinberg R.A. Modelling the molecular circuitry of cancer. Nat. Rev. Cancer. 2:2002;331-341.
47. Gonzalez-Suarez E., et al. Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO J. 20:2001;2619-2630.
48. Artandi S.E., et al. Constitutive telomerase expression promotes mammary carcinomas in aging mice. Proc. Natl. Acad. Sci. U. S. A. 99:2002;8191-8196.
49. Gonzalez-Suarez E., et al. Cooperation between p53 mutation and high telomerase transgenic expression in spontaneous cancer development. Mol. Cell. Biol. 22:2002;7291-7301.
50. Broccoli D., et al. Telomerase activation in mouse mammary tumors: lack of detectable telomere shortening and evidence for regulation of telomerase RNA with cell proliferation. Mol. Cell. Biol. 16:1996;3765-3772.
51. Akiyama M., et al. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res. 62:2002;3876-3882.
52. Forsythe H.L., et al. Retroviral-mediated expression of telomerase in normal human cells provides a selective growth advantage. Int. J. Oncol. 20:2002;1137-1143.
53. Gorbunova V., et al. Expression of human telomerase (hTERT) does not prevent stress-induced senescence in normal human fibroblasts but protects the cells from stress-induced apoptosis and necrosis. J. Biol. Chem. 277:2002;38540-38549.
54. Taggart A.K., et al. Est1p as a cell cycle-regulated activator of telomere-bound telomerase. Science. 297:2002;1023-1026.
55. Hsu H.L., et al. Ku is associated with the telomere in mammals. Proc. Natl. Acad. Sci. U. S. A. 96:1999;12454-12458.
56. Sharma G.G., et al. hTERT associates with human telomeres and enhances genomic stability and DNA repair. Oncogene. 22:2003;131-146.
57. Wong K.K., et al. Telomere dysfunction and Atm deficiency compromises organ homeostasis and accelerates ageing. Nature. 421:2003;643-648.
58. Rudolph K.L., et al. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat. Genet. 28:2001;155-159.
59. Yeager T.R., et al. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res. 59:1999;4175-4179.